Antibody drug research and development platform
贵州福彩网Antibodies have been applied in disease prevention, diagnosis and treatment for hundreds of years. In recent years, antibodies are an important new category of diagnostic and therapeutic drugs in the international pharmaceutical market due to the high specificity, effectiveness and safety features. Nowadays, antibodies have established themselves as the leading biopharmaceutical therapeutic modality.
Antibody drugs are widely used for the following purposes: 1. Reversal of organ transplantation rejection; 2. Immunological diagnosis of tumor; 3. Tumor Immunological imaging; 4. Targeted therapy of tumor; 5. Therapy for Asthma, psoriasis, rheumatoid arthritis, lupus erythematosus, acute myocardial infarction, sepsis, multiple sclerosis and other autoimmune diseases; 6. Anti-isotype specific antibody was used as molecular tumor vaccine. 7. The special purpose of multi-functional antibody (bispecific antibody, trispecific antibody, antibody cytokine fusion protein, antibody enzyme, etc.).
Since the technique of generation monoclonal antibodies has been discovered, monoclonal antibodies have showed great value as both diagnostic and therapeutic tool. With the rapid development of gene engineering techniques, various recombinant antibody fragments have become promising alternatives to monoclonal antibodies, such as humanized antibodies, monovalent small molecular antibodies (Fabs, single chain antibodies, single domain antibodies, super-variable polypeptide, etc.), polyvalent small molecular antibodies(double chain antibodies, three chain antibodies, miniature antibodies), some special modified antibodies (bispecific antibodies, antigenic antibodies, intracellular antibodies, catalytic antibodies, immunological liposome) and antibody fusion proteins (such as immunological toxins, immunological adhesion elements).
贵州福彩网The antibody phage display allowed for the first time to generate human antibodies completely in the test tube and without immunization. Antibody phage display not only allows the generation of high affinity human antibodies, it can also bypass some limitations of the immune system. For example, phage display can provide antibodies which could not be obtained by classical immunization, like antibodies against very small or non-immunogenic molecules. The establishment of these new technologies enable us to generate superior novel anti-tumor antibodies in China just like what happened in developed countries
Gegen has constructed several human small molecular antibody libraries with large a size. A variety of antibodies against tumor marker, inflammatory factor, lipid molecular, thyroxine, neurotransmitter, autoimmune disease related factor are screened out. The antibodies isolated from the libraries can reach an affinity of picogram level. They can be used not only in clinical diagnosis, but also can be used as a biological therapeutic drug candidates further. At present, Gegen has more than 10 tumor drug candidates with significant effect in preclinical experiment.